RCT · 2019
Tesamorelin Reduces Hepatic Fat in HIV-Associated NAFLD
Stanley TL, Fourman LT, Feldpausch MN, et al. · The Lancet HIV
A GHRH analogue reduced liver fat by roughly 37% relative to placebo over 12 months, with less fibrosis progression on biopsy.
Key findings
- Absolute liver-fat reduction of 4.1%
- 35% of treated participants reached hepatic fat fraction <5%
- No worsening of glycemia at group level
Limitations
Population limited to people with HIV; daily injection burden and modest sample size.